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http://dx.doi.org/10.1016/j.jfma.201Among 15 174 non-duplicated Enterobacteriaceae isolates, the prevalence of carbapenem-
nonsusceptible Enterobacteriaceae (CNSE) was about 2.5% at a teaching hospital in Taiwan
during 2010. Among 117 available isolates of CNSE, 8.6% carried genes encoding carbapene-
mases. Tigecycline and colistin were the most active agents against carbapenemase-
producing and non-producing isolates. Patients infected with CNSE had an all-cause in-hospital
mortality of 37.3%, and mortality was similar for infections from carbapenemase producers and
non-producers (14-day mortality rates: 22.2% and 21.5%; 30-day mortality rates: 22.2% and
32.3%, respectively). Continuous surveillance of CNSE is recommended in Taiwan.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The emergence and spread of carbapenem-nonsusceptible
Enterobacteriaceae (CNSE) has become a serious worldwideent of Internal Medicine,
Number 7 Chung-Shan South
.tw (J.-T. Wang).
ight ª 2012, Elsevier Taiwan LLC
2.09.021threat. Infections caused by CNSE are associated with high
mortality and there are limited treatment options.1 Several
mechanisms contribute to carbapenem resistance, with
carbapenemases being particularly challenging due to their
ability to hydrolyze almost all beta-lactams.2 There are only
limited reliable data on the prevalence, clinical presenta-
tions, and treatment outcomes of CNSE in most countries,
including Taiwan. In this report, we describe the epidemi-
ology and treatment outcomes of patients with CNSE who
were treated at a single medical center in Taiwan.& Formosan Medical Association. All rights reserved.
Figure 1 Susceptibility of isolated carbapenem-nonsuscep-
tible Enterobacteriaceae strains to various antibiotics.
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The study was conducted at the National Taiwan University
Hospital (NTUH), a 2200-bed teaching hospital that provides
primary and tertiary care. Blood cultures were processed by
the hospital microbiology laboratories using the Bactec 9240
system (Becton Dickson, Sparks, MD, USA). Organism iden-
tifications were performed by biochemical methods and the
Phoenix system (BD Diagnostic Systems, Oxford, UK). From
January 2010 to December 2010, all Enterobacteriaceae
isolated from the clinical specimens of adult inpatients
(age >18 years) that were nonsusceptible to ertapenem by
the disk diffusion method3 and preserved by the clinical
microbiology laboratories were considered as potential
study targets. Isolates with ertapenem nonsusceptibility,
confirmed by minimum inhibitory concentration (MIC) using
the agar dilution method, were classified as CNSE and were
formally enrolled in the study.4 Susceptibilities to imipenem,
meropenem, amikacin, moxifloxacin, cefepime, cefotax-
ime, flomoxef, tigecycline, and colistin were also deter-
mined by MICs.4e8 All CNSE isolates were subjected to the
modified Hodge test (MHT) and polymerase chain reaction
that targeted genes encoding K pneumoniae carbapenemase
(KPC), non-metallocarbpenemase (NMC)/Serratia marces-
cens enzyme (SME), imipenem-hydrolyzing b-lactamase
(IMI), Guyana extended spectrum-type variants (GES), New-
Delhi metallo-b-lactamase1 (NDM-1), imipenemase (IMP),
verona imipenemase (VIM), Sao Paulo metallo-b-lactamase
(SPM), German imipenemase (GIM), Seoul imipenemase
(SIM), and expanded-spectrum oxacilliniase-48 (OXA-48)
carbapenemases by the use of specific primers.2,9
A standardized case report form was used to collect
demographic and clinical data from patients with CNSE. The
Charlson comorbidity index, acute physiology and chronic
health evaluation-II (APACHE-II) score, and Pitt bacteremia
score were calculated. The definitions of immunosuppres-
sants, invasive procedures, and prior antibiotic exposure
were as previously described.10,11 All-cause 14-day and in-
hospital mortality were used as endpoints in the outcome
analysis of patients with infections.
Results
Microbiological investigations
According to computerized records, there were 15,414,
15,174, and 14,954 non-duplicated Enterobacteriaceae
isolates in 2009, 2010, and 2011, respectively, at the NTUH.
The disk diffusion method classified 589 (3.8%), 374 (2.5%),
and 339 (2.3%) of the isolates from these years as
ertapenem-nonsusceptible. A total of 142 of the 374
isolates collected in 2010 (38.0%) were available for this
study. After confirming their nonsusceptibility to ertape-
nem by MIC testing and excluding isolates from outpatients
and patients younger than 18 years, a total of 117 CNSE
isolates from 117 patients were examined. The most
common organisms were Klebsiella pneumoniae (58.1%),
Enterobacter cloacae (26.5%), and Escherichia coli (9.4%).
Based on MIC results, the most active drugs against our
isolates were colistin (90.6%), tigecycline (83.8%), mer-
openem (70.9%), amikacin (69.2%), and imipenem (57.3%).About 40% of isolates were susceptible to cefepime. Among
isolates with confirmed production of carbapenemase,
tigecycline and colistin were the two most effective agents
(Fig. 1). The sensitivity and specificity of MHT for the
detection of carbapenemases were only 80% and 77.6%,
respectively.
A total of 10 isolates (8.6%) had genes that encoded
carbapenemases (KPC: n Z 4; IMP: n Z 3; VIM: n Z 2; and
NDM-1: nZ 1). The clinical data indicated that there were
no epidemiological links between these isolates, so they
were all presumably sporadic. One patient with KPC-
producing K. pneumoniae and another with NDM-1-
producing Klebsiella oxytoca were hospitalized in main-
land China just before transfer to the NTUH.12,13 Among the
isolates that were nonsusceptible to imipenem or mer-
openem (n Z 52), the prevalence of carbapenemase
production was about 15%.
Clinical characteristics
Most of the patients were old (median age, 74 years) and
critically ill (median APACHE-II score of 17) at the time of
culture, had multiple comorbid conditions (median Charlson
comorbidity index of 5), central venous catheters, and
previous long stays in a hospital. Patients who harbored
carbapenemase-producing CNSE were more likely to have
heart failure, receive immunosuppressive therapy, and to
have no history of using anti-anaerobic agents relative to
patients who harbored non-carbapenemase-producing
CNSE. All other characteristics were similar in these two
groups (Table 1).
Seventy-six patients had infectious diseases caused by
CNSE, and the most common sites of infection were the
lower respiratory tract (34.2%), urinary tract (21.1%), and
intra-abdominal region (21.1%). Bacteremia was present in
20 patients (26.3%). Only 22 patients (28.9%) received
appropriate initial therapy (within the first 48 hours of
culture). Definitive therapies, defined as the use of an
appropriate antibiotic(s) after drug susceptibility testing
is known, were diverse and included group-2 carbape-
nems (27.7%), fourth-generation cephalosporins (23.1%),
Table 1 Demographic and clinical characteristics of 117 patients with carbapenem-nonsusceptible Enterobacteriaceae that
were carbepenemase producers or non-producers.
Characteristica Carbapenemases (n Z 10) No carbapenemase (n Z 107)
Age (y) 62.5 (52.5e75) 75 (61e80)
Gender, male (%) 6 (60.0) 60 (56.1)
Weight (kg) 55.8 (46.5e65.0) 55 (48.5e63.0)
Height (cm) 163 (150.0e166.0) 160 (155e167)
BMI (kg/m2) 22.6 (18.9e24.7) 21.4 (19.2e23.5)
CCr (mL/min) 30.3 (9.0e54.6) 36.0 (16.2e56.9)
Hospital days 12.5 (8.5e48.8) 17.0 (6.0e37.0)
Heart failure 6 (60.0%)e 24 (22.4%)e
Chronic lung disease 4 (40.0%) 30 (28.0%)
Liver disease 1 (10.0%) 29 (27.1%)
DM 5 (50.0%) 38 (35.5%)
CCr < 30 mL/min 7 (70.0%) 44 (41.1%)
Renal replacement therapy 4 (40.0%) 18 (16.8%)
Immunosuppressantsb 6 (60.0%)e 24 (22.4%)e
Malignancy 1 (10.0%) 42 (39.3%)
Charlson comorbidity index 4.5 (3.5e7.3) 5.0 (3.0e6.0)
APACHE II score 19 (8.8e27.3) 17 (9.0e26.0)
ICU stay before culture 5 (50.0%) 51 (47.7%)
ICU days 9 (6.5e40.5) 12 (6.0e19.0)
Catheter use
Endotracheal tube 5 (50.0%) 44 (41.1%)
Urinary catheter 6 (60.0%) 58 (54.2%)
Feeding tube 7 (70.0%) 73 (68.2%)
CVC 8 (80.0%) 56 (52.3%)
Drainage tube 3 (30.0%) 35 (32.7%)
Invasive procedurec 4 (44.4%) 31 (32.3%)
Recent surgery 3 (30.0%) 20 (18.7%)
Previous antibioticsd
Fluoroquinolone 1 (10.0%) 18 (16.8%)
Carbapenem 1 (10.0%) 25 (23.4%)
1e2 cephem 3 (30.0%) 26 (24.3%)
3e4 cephem 6 (60.0%) 44 (41.1%)
Glycopeptide 2 (20.0%) 24 (22.4%)
Aminoglycoside 0 (0.0%) 4 (3.7%)
Tigecycline 1 (10.0%) 2 (1.9%)
Colistin 1 (10.0%) 4 (3.8%)
Penicillins 1 (10.0%) 29 (27.1%)
Anti-pseudomonal penicillin 2 (20.0%) 28 (26.2%)
Anti-anaerobic drug 4 (40.0%) 81 (75.7%)
Community-acquired 1 (10.0%) 13 (12.1%)
APACHE II Z Acute Physiology and Ahronic Health Evaluation II; BMI Z body-mass index; CCr Z creatinine clearance; CVC Z central
venous catheter; DM Z diabetes mellitus; ICU Z intensive care unit.
a Data are median (interquartile range) for continuous variables.
b Included: (1) antineoplastic therapy within 6 weeks; (2) corticosteroids at a dose equivalent to or higher than 20 mg of prednisolone
daily for at least 2 weeks; or (3) other immunosuppressants such as azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, and
sirolimus.
c Included: (1) central venous catheterization, endoscopy, tube thoracostomy, angiography, percutaneous drainage, lumbar puncture,
chest compression, electrocardioversion, endotracheal intubation, arthrocentesis, thoracentesis, and paracentesis within 7 days; (2)
simple operations under local anesthesia within 7 days; or (3) operations under general anesthesia within 30 days.
d Defined as antibiotics used within 15 days before cultures.
e p < 0.05.
494 C.-C. Lai et al.aminoglycosides (13.8%), tigecycline (12.3%), and fluo-
roquinolones (12.3%). Combination therapy was given to
20.0% of patients, and imipenem plus amikacin was the
most common combination. Cefepime (33.3%) and tigecy-
cline (22.2%) were the most common agents used asdefinitive therapy for patients with carbapenemase
producers. A total of 75.7% of patients had clinical success,
and the all-cause 14-day and in-hospital mortality rates
were 21.6% and 37.3%, respectively. In bacteremic
patients, the all-cause 14-day mortality was 36.8%. Clinical
Table 2 Infection sites and clinical outcomes of 76 patients infected with carbapenem-nonsusceptible Enterobacteriaceae
that were carbepenemase producers or non-producers.
Variables Carbapenemase (n Z 9) No carbapenemase (n Z 67)
Infection site
Intra-abdominal infection 3 (33.3%) 13 (19.4%)
Urinary tract infection 2 (22.2%) 14 (20.9%)
Skin and soft tissue infection 0 (0.0%) 10 (14.9%)
Lower respiratory tract infection 3 (33.3%) 23 (34.3%)
Primary bacteremiaa 2 (22.2%) 4 (6.0%)
Secondary bacteremia 1 (11.1%) 13 (19.4%)
Pitt score, median 6 3
Appropriate initial antibiotics 2 (22.2%) 20 (30.3%)
Treatment outcomes
Defervescence (d)b 2 (1e6) 1 (1e3)
Clinical success 7 (77.8%) 49 (75.4%)
14-d mortality 2 (22.2%) 14 (21.5%)
30-d mortality 2 (22.2%) 21 (32.3%)
In-hospital mortality 2 (22.2%) 26 (39.4%)
a Included catheter-related bloodstream infection.
b Data are median (interquartile range).
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with carbapenemase-producing and non-producing strains
(Table 2). Patients treated with a carbapenem- or fourth-
generation cephalosporin-based regimen as definite thera-
pies had similar clinical outcomes. The tigecycline-based
regimen was associated with a lower rate of clinical
success, however, compared to carbapenem-based therapy
[5/10 (50%) vs. 18/20 (90%), p Z 0.05].Discussion
During 1999e2007, about 1% of E. coli isolates in Taiwan
were ertapenem-nonsusceptible, and resistance was
mainly from AmpC overexpression and porin under-
expression, with no carbapenemase producers detected at
that time.14 In our study, the prevalence of CNSE and the
proportion of carbapenemase-producing isolates were both
increasing. The burden of CNSE in Taiwan, however,
remains relatively low compared to some Western coun-
tries.15 In accordance with previous studies, the MHT in our
study was suboptimal for the detection of carbapene-
mases.16 The patients in our study tended to be elderly and
have multiple comorbidities, and 71.1% received inappro-
priate initial therapy, although clinical success was ach-
ieved in 75.7% of our cohort. It remains uncertain whether
infections caused by CNSE are associated with worse
outcomes relative to those caused by carbapenem-
susceptible Enterobacteriaceae.
In this preliminary study, we found that group-2 carbape-
nems were active against more than half of the ertapenem-
nonsusceptible isolates. Previous research has advocated the
useof group-2 carbapenemsasa reasonable treatmentoption
against ertapenem-nonsusceptible Enterobacteriaceae,
especially in geographic areas where carbapenemase-
producing Enterobacteriaceae are uncommon.17
Our molecular methods to detect carbapenemases were
unable to identify some new variants belonging to the 11major carbapenemase groups noted among the Enter-
obacteriaceae. These new variants, however, were either
quite rare or were only found in limited areas. Recently,
a study from 11 Taiwanese hospitals showed that the prev-
alence of carbapenemase producers among CNSE was 9.5%,
and only KPC along with IMP group carbapenemases were
found.18 Although their prevalence rate (9.5%) is slightly
higher than ours (8.6%), their study was in an “outbreak”
situation, which would lead to an overestimation of the
prevalence. Therefore, although our primers could not
identify all of the carbapenemases, the impact may be
minimal. Our data were also limited due to the study’s
retrospective design, with small sample size at a single
institution. As a result, the comparisons of clinical outcomes
between carbapenemase producers and non-producing
strains or between different regimensmight be inconclusive.
However, our data pointed out the possibility that determi-
nation of carbapenem resistance was more relevant to clin-
ical outcomes than the detection of carbapenemase
production, with similar outcomes of infections caused by
carbapenemase-producing and non-producing CNSE.
In conclusion, this preliminary study demonstrated that
carbapenemase-producing Enterobacteriaceae remain
uncommon in Taiwan. Tigecycline and colistin were the
most active agents against carbapenemase-producing
isolates. The clinical outcomes were similar for patients
infected by carbapenemase-producing and non-producing
CNSE. CNSE has increased rapidly in several geographic
areas during recent years, so continuous monitoring of CNSE
in Taiwan is still highly recommended.Funding
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